Inhibitory effect of pumpkin protein on expression of Notch signal in RPMI8226 myeloma cells.
10.7534/j.issn.1009-2137.2014.04.023
- Author:
Ting-Bo LIU
1
;
Pei YANG
2
;
Jie-Ming XIE
3
;
Jian-Da HU
4
Author Information
1. Fujian Institute of Hematology,Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China. E-mail: liutb@medmail.com.cn.
2. Fujian Provincial College of Medical Sciences, Fuzhou 350001, Fujian Province, China.
3. Pharmaceutical College of Fujian Medical University, Fuzhou 350004, Fujian Province, China.
4. Fujian Institute of Hematology,Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Cell Line, Tumor;
Humans;
Intercellular Signaling Peptides and Proteins;
metabolism;
Jagged-2 Protein;
Membrane Proteins;
metabolism;
Multiple Myeloma;
metabolism;
NF-kappa B;
metabolism;
Plant Proteins;
pharmacology;
Proto-Oncogene Proteins c-akt;
metabolism;
Receptor, Notch1;
metabolism;
Receptors, Notch;
metabolism;
Signal Transduction;
drug effects
- From:
Journal of Experimental Hematology
2014;22(4):1012-1015
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the inhibitory effect of pumpkin protein (cucurmosin, CUS) on proliferation of RPMI8226 myeloma cells in vitro and its mechanism. Western blot was used to detect the expression level of Notch-1, Jagged-2, P-Akt and NF-KB in the myeloma cells treated by different concentrations of CUS. The results demonstrated that CUS could down-regulate the protein expression levels of Notch1, Jagged-2, P-Akt and NF-KB in the myeloma cells and with time-and concentration-dependent way, at the same time CUS could also decrease the expressions of BCL-2 and P-Akt. It is concluded that CUS can obviously inhibit the RPMI8226 cell proliferation in vitro, down-regulate the expression levels of Notch signal and its down-stream target genes. Therefore, Notch signaling pathway can be used as a new treatment target for multiple myeloma, and CUS may be become a potential new drug for regulating Notch signaling pathway.
